SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

120 device types granted exemption from FDA 510(k) Lung sound monitors, oscillometers, among products no longer needing certification

Welch Allyn partners with PointClickCare to develop senior care solution Connecting data from patient monitor to EHR

Feature: Tomosynthesis: A new gold standard? Find out if tomosynthesis will become the new standard of mamography screening

Olympus hit with new superbug duodenoscope lawsuit More litigation stemming from UCLA Medical Center outbreak

Joint Commission rolls out XR-29-esque rules today New standards require protocol, dose and benchmark changes

Future of clinician training ‘left to chance’ due to lack of medical education research More funding is needed in U.S. and England

Low-dose radiation: Guilty until proven innocent? Researchers call evidence linking cancer to low-dose exposure flawed

Hospital in India treats 10,000th patient with RapidArc radiotherapy About 20 percent of treatments are performed free of charge

First 3-D heart made from multiple imaging techniques Resulting model first step in efficacy study for surgical planning using 3-D printing

Mevion brings Ohio one step closer to proton therapy The superconducting cyclotron accelerator has been delivered

Amyloid imaging lights up SNM 2012

by Loren Bonner , DOTmed News Online Editor
Presenters at the 59th annual SNM meeting in Miami Beach, Fla., unveiled an array of breakthrough research and new techniques to detect evidence of Alzheimer's in living patients -- including, possibly, in asymptomatic populations.

Researchers know that beta-amyloid plaque can build up in the brain several years before an individual shows any signs of dementia. And many scientists believe that this plaque can kill vital neural pathways that are responsible for language, memory and behavior.

Story Continues Below Advertisement

Up To 80% Off on Medical Display Monitors! Call (832) 877-1250

We are wholesaler of pre-owned and new brand name medical display monitors. We have top brand grayscale and color LCD monitors with up to 3 years warranty and at least a 30 days money back guarantee at up to 80% off MSRP. DOTmed Certified



"Molecular imaging can detect signs of Alzheimer's disease many years before patients develop dementia. It can do this because it can target beta-amyloid," says Dr. Christopher Rowe, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle study of aging and professor of nuclear medicine at Austin Hospital in Melbourne, Australia.

In one of the studies presented by Rowe's team, PET was combined with an F-18 imaging agent. Subjects who showed high levels of the tracer during imaging had an 80 percent chance of developing Alzheimer's within two years, according to study findings.

Research also found that beta-amyloid plaque in the brain was not only involved in the pathology of Alzheimer's disease but also preceded mild cognitive function.

"For those with mild memory problems who had a positive scan, 66 percent of these people progressed to dementia over three years. This compares to only 7 percent of those with a negative scan," says Rowe.

Rowe highlighted findings on this study at the meeting, which included 194 healthy elderly subjects, 92 subjects with mild cognitive impairment, and 70 subjects with Alzheimer's. C-11 Pittsburgh compound B (PiB) combined with PET was used to gauge amyloid burden in the brain.

"This is an opportunity to find the patient who has Alzheimer's and intervene with treatments as they become available," says Rowe.

He pointed out that being able to correctly identify which patients have Alzheimer's and which don't is a necessary stepping stone for developing potential drugs and therapies to treat the disease.

Alzheimer's can only be detected in a patient after death-- by studying postmortem brain samples with beta-amyloid plaque.

Currently, no reliable treatment exists for Alzheimer's patients and the screening tests that do exist are unreliable and limited in their ability to identify the disease early.

New biomarkers emerge

Any PET amyloid imaging test must begin with a biomarker. This year's SNM meeting presented some promising amyloid imaging agents in development that will help clinicians detect Alzheimer's in living patients.

Continue reading Amyloid imaging lights up SNM 2012...
  Pages: 1 - 2 - 3 >>

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2015 DOTmed.com, Inc.
ALL RIGHTS RESERVED